Stock_Titan Posted - 6 days ago

$ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results https://www.stocktitan.net/news/ALNY/alnylam-to-webcast-conference-call-discussing-first-quarter-2024-7e2col0yhorp.html

opgenopgen Posted - 1 week ago

$ALNY U.S. High Growth Tech and AI Stocks!!! https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/us?via=bullmarketstocks

StockInvest_us Posted - 2 weeks ago

Signal alert: $ALNY - GoldenStar https://stockinvest.us/l/nBdXq8zcUm

Quantumup Posted - 2 weeks ago

Wolfe Research $IONS Upgrading to Outperform on Catalysts (HELIOS-B & more)/Revenue Potential (SHTG & more) Sees HELIOS-B readout as risky cat, but expects favorable R/R4 $IONS movement (more so than $ALNY). Now models $2.1B peak rev for olezarsen. Pelacarsen not in model=pot upside. $vrtx

tradingtwenty Posted - 2 weeks ago

$ALNY has trended 15 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 07, 2024 08:00 AM: Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care... Link: https://tradingtwenty.com/news/420901/alnylam-presents-positive-results-from-the-kardia-2-phase-2-study-of-zilebesiran-added-to-standard-of-care-antihypertensives-in-patients-with-inadequately-controlled-hypertension

Stock_Titan Posted - 2 weeks ago

$ALNY Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension https://www.stocktitan.net/news/ALNY/alnylam-presents-positive-results-from-the-kardia-2-phase-2-study-of-zkq1hsvkficn.html

SorosOfPharmaeuticals Posted - 2 weeks ago

$ALNY With the late breaker presented on 7th April on zileberisan. Anyone want to guess impact on share price? https://investors.alnylam.com/press-release?id=28036

lextrading Posted - 03/28/24

$ALNY High risk/high reward set up. High risk because it's a biotech. Next support is at $120 if the channel breaks.

jaydilks Posted - 03/27/24

$VXF Best performers today. $MRVL $ALNY $RBLX

pilobious Posted - 03/27/24

$ALNY chip rally finished it appears. I’m moving into biotech. ALNY and ADMA. I’m far from a biotech expert. Constructive criticism invited.

Stu512 Posted - 03/26/24

$ALNY Like their call on $BLUE PT $11 ..today at $1.39 !!! Oh ya , listen to HCW

Stu512 Posted - 03/26/24

$ALNY like their call on $SOL at $25, headed to $35 , today at $1.98

TeresaTrades Posted - 1 month ago

Heavy options volume $MJ $LULU $ALNY $PZZA $CRON

pilobious Posted - 1 month ago

$ALNY this sells off every day. $150 this morning got whacked. I’m down big and holding.

Quantumup Posted - 1 month ago

Raymond James resumed $BBIO Outperform/$45: Believes oral TTR-stabilizers will remain the gold-standard 1st-line Tx for pts w/ ATTR-CM. Re: IP overhang: there are +VE signs $PFE will be successful; If patent holds, ests $BBIO = $3B peak/20% of est'd $15B TAM, w/ uncertainty $1.6B. $alny

Stock_Titan Posted - 1 month ago

$ALNY Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session https://www.stocktitan.net/news/ALNY/alnylam-to-webcast-investor-event-to-discuss-results-from-kardia-2-em6s08uotu95.html

G101SPM Posted - 1 month ago

@S_Franconi per request: $ALNY carries SPM 83.25 tag.

S_Franconi Posted - 1 month ago

@G101SPM Can you run $ALNY?

Quantumup Posted - 1 month ago

BMO Capital $SLN "Weakness a Unique Opportunity to buy the dip;" Reiterated as Top Pick~$67/OP Despite the fact Zirlesiran data "met/beat" inv expys, SLN is down. BMO reits high conviction on 2 de-risked/differentiated programs=multi-billion$ comm opps; low valuation vs peers; '24 catalyst. $alny $ions $arwr

ksoption Posted - 1 month ago

$ALNY

Stock_Titan Posted - 1 month ago

$ALNY Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease https://www.stocktitan.net/news/ALNY/alnylam-launches-hereditary-attr-h-attr-amyloidosis-campaign-to-help-931mt392pyga.html

addtocart Posted - 1 month ago

$ALNY yeah this looks good here

swingingtech Posted - 1 month ago

$ALNY $RHHBY https://wallstreetwaves.com/roche-alnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-as-promising-op

Thestocktraderhubzee Posted - 1 month ago

$ALNY HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price Target

piano91 Posted - 1 month ago

$ALNY 1.2 billion people effected here and zilebesiran will be standard of care. Roche marketing worldwide and Alnylam in US. Should bring over 3-4B in rev

DonCorleone77 Posted - 1 month ago

$ALNY Alnylam reports KARDIA-2 zilebesiran study met primary endpoint of lower SBP Alnylam Pharmaceuticals announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen AGT in development for the treatment of hypertension, met the primary endpoint showing that zilebesiran resulted in clinically and statistically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure SBP at Month 3 as measured by ambulatory blood pressure monitoring ABPM in each of three independent patient cohorts receiving the standardized background therapies of either a thiazide-like diuretic or indapamide, calcium channel blocker, amlodipine, or angiotensin receptor blocker ot olmesartan. Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives. The Company believes these findings support further development....

Stock_Titan Posted - 1 month ago

$ALNY Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives https://www.stocktitan.net/news/ALNY/alnylam-reports-positive-kardia-2-topline-study-results-tt3pgu60yh9q.html

valueforme Posted - 1 month ago

$OMGA Ha! The CEO has mentioned during this podcast that the obesity program that they are going to work on with Novo Nordisk will target adipose tissue. Hmm, where I've heard this before.. Let me think. Ah, yes, INHBE programs that $WVE , $ARWR and $ALNY are going to file IND for over next 12 months. So this is getting even more interesting. Not just s battle of siRNA chemistry approaches, but also epigenetics down regulation from OMGA as an alternative. O boy, o boy, o boy, this is going to be a fun decade https://thebioreport.podbean.com/e/correcting-gene-dysregulation-to-treat-diseases/

Biotech_Beast Posted - 02/28/24

$VIR has something promising in Hepatitis Delta and more data are on tap in Q2'24. Additional Hepatitis B data in Q4'24. $ALNY $GSK https://seekingalpha.com/article/4674087-vir-biotechnology-stock-making-progress-in-hepatitis-b-hepatitis-delta

JGNYC Posted - 02/27/24

$ALNY waiting for entry